Therapy Areas: Respiratory
Insilico initiates Rentosertib Phase III clinical trial for idiopathic pulmonary fibrosis
8 July 2026 - Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Tuesday the initiation of the Phase III clinical trial for Rentosertib, its potentially first-in-class ora...
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
2 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Thursday reported positive Phase III results from the Krascendo 1 trial evaluating investig...
Abbisko Therapeutics and AstraZeneca collaborate to conduct combination clinical trial for NSCLC
2 July 2026 - Chinese biopharmaceutical company Abbisko Therapeutics Co Ltd (HKEX:02256) announced on Wednesday that it has entered into a strategic collaboration agreement with biopharmaceutical comp...
Co-Diagnostics advances toward FDA filing after completing clinical validation for respiratory point-of-care test
1 July 2026 - Molecular diagnostics company Co-Diagnostics Inc (Nasdaq: CODX) disclosed on Monday that it has completed clinical and analytical performance studies supporting its planned FDA submissio...
Nuvation Bio's taletrectinib Marketing Authorisation Application for advanced ROS1-positive non-small cell lung cancer treatment validated in UK
30 June 2026 - Nuvation Bio (NYSE: NUVB), a New York-based global oncology company involved in cancer treatment, announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA)...
Grünenthal completes Nociceptin Receptor (NOP) Agonist Phase I trial
30 June 2026 - Grünenthal, a Germany-based pharmaceutical company, announced on Monday that the company has successfully concluded a Phase I trial evaluating the safety and tolerability of its pr...